"The spasticity was the worst part. Not the fatigue, not the vision problems — the spasticity. My legs would seize up at night and I'd wake up screaming. Baclofen helped some, but it made me so foggy I couldn't work. Cannabis gave me the spasticity control without the fog."
— David K., 52, software engineer, Seattle, Washington
David was 38 when he noticed the first symptoms — a patch of numbness on his left thigh that wouldn't go away, followed by an episode of optic neuritis that temporarily blurred his vision. His neurologist ordered an MRI. The white matter lesions were unmistakable. Relapsing-remitting multiple sclerosis.
"I was actually relieved it had a name. I'd been worried it was something worse. My neurologist was excellent — she put me on a disease-modifying therapy immediately and explained that we had good tools to slow the disease. What she couldn't fully control were the symptoms."
Over the following decade, David's disease-modifying therapy kept his relapse rate low. But the accumulated neurological damage produced persistent symptoms: spasticity in his legs, neuropathic pain described as "burning and electric," bladder urgency, and fatigue. These symptoms were managed with a growing list of medications — baclofen for spasticity, gabapentin for neuropathic pain, oxybutynin for bladder, modafinil for fatigue.
By his late 40s, David was taking seven medications daily. The side effects were compounding: baclofen caused cognitive slowing that affected his work as a software engineer. Gabapentin caused weight gain and sedation. The combination left him feeling, as he put it, "like I was thinking through wet concrete."
"I was managing the disease but losing my life to the medications. I couldn't do complex programming work after noon because the baclofen had kicked in fully. I was gaining weight. I was sleeping 10 hours and still exhausted. Something had to change."
His neurologist, aware of his concerns, mentioned that nabiximols — a THC/CBD oromucosal spray approved for MS spasticity in Canada and Europe — had strong clinical trial evidence for exactly his situation. It wasn't available in the U.S. as an approved medication, but she could recommend medical cannabis as an alternative.
David worked with a cannabis-specialized physician to develop a protocol modeled on the nabiximols clinical trial data: a roughly 1:1 THC:CBD ratio, administered sublingually, titrated to effect. He started with 2.5mg THC / 2.5mg CBD twice daily and increased gradually over four weeks.
"The first week, I didn't notice much. By week three, I realized I'd slept through the night twice without leg spasms waking me up. That hadn't happened in years." By week six, he was at 5mg THC / 5mg CBD three times daily — morning, afternoon, and bedtime — and his spasticity scores had improved significantly.
Critically, the cognitive side effects were far milder than baclofen. "I could still think clearly. I could still code. The cannabis was doing what the baclofen did for spasticity without the fog." With his neurologist's guidance, he gradually tapered his baclofen dose by 50% over three months.
The neuropathic pain — the burning, electric sensations in his feet and lower legs — proved more challenging. Gabapentin had been partially effective but at the cost of significant sedation. He found that higher-CBD formulations (4:1 CBD:THC) taken during the day provided meaningful pain relief without the sedation of gabapentin.
"The neuropathic pain isn't gone. But it's gone from a 7 out of 10 to a 3 or 4. I can work through it. I can exercise. I can have a normal day." He reduced his gabapentin dose by 40% over six months, with his neurologist monitoring his pain scores and neurological function throughout.
Beyond spasticity and pain, David noticed improvements he hadn't anticipated. His sleep quality improved substantially — fewer nighttime awakenings, more restorative sleep. His mood stabilized. "MS has a significant depression component that I'd been managing with an antidepressant. About four months into cannabis, my psychiatrist and I agreed I could try tapering the antidepressant. I've been off it for a year now."
He also found that cannabis helped with the bladder urgency that had been a significant quality-of-life issue. "I don't know if that's a direct effect or just that I'm less anxious and tense overall, but the urgency is much better."
David is now 52. He continues his disease-modifying therapy — "that's non-negotiable, that's what's keeping the disease from progressing" — and uses cannabis as his primary symptomatic treatment. His medication list has gone from seven drugs to four. He works full-time. He hikes on weekends.
"I want to be clear about what cannabis has and hasn't done. It hasn't cured my MS. It hasn't stopped the disease. What it's done is give me my functional life back by managing the symptoms better than the alternatives, with fewer side effects. That's not nothing. For me, that's everything."
David's experience is supported by the strongest evidence base in cannabis medicine. Nabiximols (Sativex — 1:1 THC:CBD oromucosal spray) is approved for MS spasticity in over 30 countries based on multiple Phase III RCTs. A 2012 Cochrane review of 12 trials found cannabinoids significantly reduced spasticity scores, pain, and sleep disturbance in MS patients. The American Academy of Neurology's 2014 evidence review found oral cannabinoids "probably effective" for spasticity and central pain in MS — the highest evidence rating given to any cannabis application at that time. The National MS Society supports patient access to medical cannabis and physician-patient discussions about its use.